![Grégory Olszowy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Origen de la red de primer grado Grégory Olszowy.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Dôm Finance SAS
![]() Dôm Finance SAS Investment ManagersFinance Dôm Finance SAS is an independent French asset management firm headquartered in Paris. The firm was founded by Philippe Douillet and Eric Marmousez in 2004. Dôm Finance manages investment vehicles for institutional and private clients. The firm is a signatory to the Carbon Disclosure Project, a non-profit NGO that publicly reports environmental data on more than 2500 issuers.
11
| Private Company | Investment Managers | 11 |
IT Asset Management SA
![]() IT Asset Management SA Investment ManagersFinance IT Asset Management SA (ITAM), established in 1994, is an independent asset management firm based in Paris, France. ITAM is wholly-owned by their management and employees. The firm provides financial advisory services and manages discretionary portfolios and mutual funds (FCPs and a compartment of a Luxembourg-based SICAV) for institutional clients and private individuals.
2
| Extinct | Investment Managers | 2 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Grégory Olszowy a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
University of Adelaide | College/University | Doctorate Degree | |
Sciences Po Strasbourg | College/University | Graduate Degree | |
iM Global Partner SAS
![]() iM Global Partner SAS Investment ManagersFinance iM Global Partner SAS is a worldwide asset management network that selects and builds long-term partnerships with talented and independent asset management companies through direct capital ownership. The company is based in Paris, FR, and has subsidiaries in the United Kingdom, Luxembourg, Spain, the United States, and France. The French company provides its clients with access to the best management strategies of its partners through a wide range of investment solutions, including the Oyster range, a SICAV, mutual funds, and ETFs dedicated to US investors. iM Global Partner has an experienced business development team present in 10 locations across the world. The company was founded in 2012, and the CEO is Philippe Couvrecelle. The company represents around 35 billion USD of assets under management as of end July 2021. iM Global Partner was acquired by iM Square SAS from Cie Financière Jacques Coeur SAS. | Investment Managers | Head-Fixed Income Invts | |
Crédit Mutuel Asset Management SA
![]() Crédit Mutuel Asset Management SA Investment ManagersFinance Crédit Mutuel Asset Management SA (CM-AM) is an asset management firm headquartered in Paris, France. The firm was founded in 1992 and is a subsidiary of Groupe Crédit Mutuel Centre Est Europe SA, ultimately held by Confederation Nationale Crédit Mutuel SA. CM-AM offers a complete range of funds to various investors. | Investment Managers | Portfolio Manager-Equities | |
Finaltis SA
![]() Finaltis SA Investment ManagersFinance Finaltis SA is an alternative investment management firm headquartered in Paris, France. It was founded by Denis Beaudoin in 2001 and is a subsidiary of Finaltis SAS. The firm offers alternative investment solutions to institutional and private clients. Finaltis is a signatory of the United Nations Principles for Responsible Investment (UNPRI). | Investment Managers | Portfolio Manager-Equities | |
FOURPOINTS Investment Managers SAS
![]() FOURPOINTS Investment Managers SAS Investment ManagersFinance FOURPOINTS Investment Managers SAS (FOURPOINTS) is an investment management subsidiary of Homa Capital SA in France. The firm was founded by Béatrice Philippe in 2012 when PIM Gestion France and IT Asset Management merged. Headquartered in Paris, FOURPOINTS offers investment solutions for retail, institutional and CGPI clients. It is available through a wide variety of management methods: management under mandate, managed management, equity funds and diversified funds of funds. | Investment Managers | Analyst-Equity | |
Invex Therapeutics Ltd. (United Kingdom) | Director/Board Member | ||
Warambi Ltd. | Corporate Officer/Principal | ||
INVEX THERAPEUTICS LTD | Biotechnology | Founder | |
The University of New South Wales | College/University | Undergraduate Degree | |
Tocqueville Finance SA
![]() Tocqueville Finance SA Investment ManagersFinance Tocqueville Finance SA is the asset management subsidiary of La Banque Postale SA, which is owned by La Poste SA in France. Headquartered in Paris, the firm was founded in 1991 and offers tailor-made investment solutions to private individual and institutional clients. | Investment Managers | Chief Investment Officer | |
Parvulus Suisse SA
![]() Parvulus Suisse SA Medical SpecialtiesHealth Technology Parvulus Suisse SA provides medical technology. It focused on commercializing devices for cardiac surgery distribution, manufacturing, sales and distribution. The company was founded in March 20011 and is headquartered in Lonay, Switzerland. | Medical Specialties | Chief Executive Officer | |
Auris Gestion SA
![]() Auris Gestion SA Investment ManagersFinance Auris Gestion SA is an independent wealth management firm headquartered in Paris, France. The firm was founded as Auris Gestion Privée SA in 2004 by former managers and executives of Lombard Odier and Neuflize, Paribas and Rothschild. Auris Gestion provides discretionary management services, based on stock selection across asset classes, for individual and institutional clients such as private investors, business executives, families, artists, top athletes and associations. | Investment Managers | Head-Equity Investments | |
Korda & Co. | Investment Managers | Chief Investment Officer | |
BIOFRONTERA AG | Pharmaceuticals: Major | Director/Board Member | |
Spark Therapeutics Ireland Ltd.
![]() Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Chief Executive Officer | |
4SC AG | Biotechnology | Chief Executive Officer | |
RESONANCE HEALTH LIMITED | Medical/Nursing Services | Director/Board Member | |
Warambi SARL | Director/Board Member | ||
JDS BioPharma Pty Ltd. | Director/Board Member | ||
ACTINOGEN MEDICAL LIMITED | Pharmaceuticals: Other | Chairman | |
Corticrine Ltd.
![]() Corticrine Ltd. Pharmaceuticals: MajorHealth Technology Part of Actinogen Medical Ltd., Corticrine Ltd. develops and manufactures drugs. The company is based in Edinburgh, UK. Corticrine was acquired by Actinogen Medical Ltd. on December 01, 2014 for $4.97 million. | Pharmaceuticals: Major | Director/Board Member |
Estadísticas
Internacional
Francia | 19 |
Australia | 7 |
Reino Unido | 7 |
Alemania | 3 |
Suiza | 2 |
Sectorial
Finance | 16 |
Health Technology | 10 |
Consumer Services | 4 |
Health Services | 2 |
Distribution Services | 2 |
Operativa
Portfolio Manager-Equities | 21 |
Director/Board Member | 12 |
Portfolio Manager-Fixed Income | 9 |
Chief Executive Officer | 5 |
Chief Investment Officer | 5 |
Las relaciones más conectadas
- Bolsa de valores
- Insiders
- Grégory Olszowy
- Conexiones Empresas